US-based biotechnology company Inceptor Bio has dosed the first subject in the investigator-initiated trial of its lead programme, IB-T101, for clear cell renal cell carcinoma (ccRCC). The trial will ...
Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended to slow disease progression in subjects with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry ...
Carlsbad, CA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (PALI) (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing ...
NEW YORK, June 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing ...
Adicet Bio has dosed the first systemic sclerosis (SSc) subject in the Phase I trial’s second cohort evaluating the investigational allogeneic gamma delta chimeric antigen receptor (CAR) T cell ...
ML Bio Solutions has initiated a Phase 1 clinical trial of BBP-418 in healthy volunteers ML Bio Solutions’ sponsored lead-in study is enrolling patients with LGMD2i across twelve sites in the U.S. and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results